Cancer immunity and immunotherapy beyond COVID-19-Reference-Cited by-同舟云学术

Cancer immunity and immunotherapy beyond COVID-19

Published:2023-03-30 Issue:7 Volume:72 Page:2541-2548
ISSN:0340-7004
Container-title:Cancer Immunology, Immunotherapy
language:en
Short-container-title:Cancer Immunol Immunother

Author:

Bellone Matteo,Brevi Arianna,Bronte Vincenzo,Dusi Silvia,Ferrucci Pier Francesco,Nisticò Paola,Rosato Antonio,Russo Vincenzo,Sica Antonio,Toietta Gabriele,Colombo Mario Paolo

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology,Immunology,Immunology and Allergy

Link

https://link.springer.com/content/pdf/10.1007/s00262-023-03411-9.pdf

Reference37 articles.

1. Morad G, Helmink BA, Sharma P, Wargo JA (2021) Hallmarks of response, resistance, and toxicity to immune checkpoint blockade. Cell 184:5309–5337. https://doi.org/10.1016/j.cell.2021.09.020

2. Landow SM, Gjelsvik A, Weinstock MA (2017) Mortality burden and prognosis of thin melanomas overall and by subcategory of thickness, SEER registry data, 1992–2013. J Am Acad Dermatol 76:258–263. https://doi.org/10.1016/j.jaad.2016.10.018

3. Whiteman DC, Baade PD, Olsen CM (2015) More people die from thin melanomas (1 mm) than from thick melanomas (>4 mm) in Queensland. Austr J Invest Dermatol 135:1190–1193. https://doi.org/10.1038/jid.2014.452

4. Eggermont AMM, Bellomo D, Arias-Mejias SM et al (2020) Identification of stage I/IIA melanoma patients at high risk for disease relapse using a clinicopathologic and gene expression model. Eur J Cancer 140:11–18. https://doi.org/10.1016/j.ejca.2020.08.029

5. Casucci M, Nicolis di Robilant B, Falcone L et al (2013) CD44v6-targeted T cells mediate potent antitumor effects against acute myeloid leukemia and multiple myeloma. Blood 122:3461–3472. https://doi.org/10.1182/blood-2013-04-493361